WINT.OQ
Latest Trade
2.30USDChange
0.00(0.00%)Volume
295Today's Range
-
--52 Week Range
-
10.03As of on the NASDAQ ∙ Minimum 15 minute delay
March 29 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR END 2020 FINANCIAL RESULTS AND PROVIDES KEY BUSINESS UPDATES.Q4 LOSS PER SHARE $0.44.AS OF DEC 30, 2020, CO REPORTED CASH, CASH EQUIVALENTS OF $16.9 MILLION.
March 22 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS.WINDTREE THERAPEUTICS INC - INTENDS TO USE NET PROCEEDS FROM PROPOSED OFFERING FOR CONTINUED ADVANCEMENT OF ITS PRODUCT CANDIDATE ISTAROXIME.
Nov 16 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES KEY BUSINESS UPDATES.Q3 LOSS PER SHARE $0.54.AS OF SEPTEMBER 30, 2020, CO REPORTED CASH AND CASH EQUIVALENTS OF $22.4 MILLION.WILL BE ABLE TO FUND OPERATIONS THROUGH AT LEAST NEXT TWELVE MONTHS.
Sept 29 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR A PHASE 2 CLINICAL TRIAL STUDYING KL4 SURFACTANT IN ACUTE LUNG INJURY IN ADULTS WITH COVID-19.WINDTREE THERAPEUTICS INC - SEES POTENTIAL EXPANDED COVID-19 PROGRAM AS NEXT STEP.WINDTREE THERAPEUTICS INC - PLANS TO START INITIAL COVID-19 PHASE 2 STUDY WITHIN NEXT SEVERAL WEEKS.WINDTREE - IF INITIAL PHASE 2 STUDY RESULTS SHOW ADEQUATE SAFETY & EFFICACY UNDER COVID-19 PROGRAM, WOULD PLAN TO INITIATE 2 ADDITIONAL CLINICAL TRIALS.
Sept 17 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $75 MILLION - SEC FILING.
July 20 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE APPOINTS JOHN HAMILL AS CHIEF FINANCIAL OFFICER.WINDTREE APPOINTS JOHN HAMILL AS CHIEF FINANCIAL OFFICER.WINDTREE THERAPEUTICS INC - JOHN HAMILL IS REPLACING FORMER CFO, JOHN TATTORY.
May 20 (Reuters) - Windtree Therapeutics Inc <WINT.O>::WINDTREE THERAPEUTICS ANNOUNCES PRICING OF $20.0 MILLION PUBLIC OFFERING AND UPLISTING TO THE NASDAQ CAPITAL MARKET.WINDTREE THERAPEUTICS INC - PRICING OF PUBLIC OFFERING OF 2.8 MILLION UNITS AT A PRICE TO PUBLIC OF $7.25 PER UNIT.WINDTREE THERAPEUTICS INC - IN CONNECTION WITH OFFERING, ITS COMMON STOCK HAS BEEN APPROVED FOR LISTING ON NASDAQ CAPITAL MARKET.WINDTREE THERAPEUTICS INC - WILL BEGIN TRADING ON NASDAQ CAPITAL MARKET UNDER SYMBOL "WINT" ON MAY 20, 2020.
Jan 27 (Reuters) - Windtree Therapeutics Inc <WINT.PK>::WINDTREE THERAPEUTICS INC - HAVE APPLIED TO LIST COMMON STOCK ON THE NASDAQ CAPITAL MARKET, OR NASDAQ, UNDER THE SYMBOL "WINT".
June 29 (Reuters) - Windtree Therapeutics Inc <WINT.PK>::Windtree announces top-line results from aerosurf phase 2B clinical trial for the treatment of respiratory distress syndrome (RDS) in premature infants.
May 22 (Reuters) - Windtree Therapeutics Inc <WINT.PK>:Windtree receives sbir grant in continued support of aerosurf® phase 2b clinical trial.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.